MIB1 and central nervous system cancer: In the study from Widhalm et al., the lesions with negative ALA fluorescence demonstrated lower MIB-1 labeling and lower PETmax, compared to the more malignant WHO Grade III gliomas, supporting that, with lower features of malignancy, there is less frequent ALA fluorescence labeling [30].